These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37100717)

  • 1. Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study.
    Nakagawa H; Igarashi A; Saeki H; Kabashima K; Tamaki T; Kaino H; Miwa Y
    Allergol Int; 2024 Jan; 73(1):137-142. PubMed ID: 37100717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Murata R; Kaino H; Nagata T
    J Dermatol; 2020 Feb; 47(2):114-120. PubMed ID: 31820485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
    J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kabashima K; Oda M; Nagata T
    J Am Acad Dermatol; 2021 Oct; 85(4):854-862. PubMed ID: 34118298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Oda M; Kabashima K; Nagata T
    J Allergy Clin Immunol; 2019 Dec; 144(6):1575-1583. PubMed ID: 31425780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials.
    Fukuie T; Toyama H; Tanaka M; Ohashi-Doi K; Kabashima K
    Pediatr Int; 2024; 66(1):e15798. PubMed ID: 39373522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.
    Nakagawa H; Nemoto O; Igarashi A; Nagata T
    Br J Dermatol; 2018 Feb; 178(2):424-432. PubMed ID: 28960254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study.
    Worm M; Bauer A; Elsner P; Mahler V; Molin S; Nielsen TSS
    Br J Dermatol; 2020 May; 182(5):1103-1110. PubMed ID: 31466119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
    Worm M; Thyssen JP; Schliemann S; Bauer A; Shi VY; Ehst B; Tillmann S; Korn S; Resen K; Agner T
    Br J Dermatol; 2022 Jul; 187(1):42-51. PubMed ID: 35084738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
    Nakagawa H; Nemoto O; Yamada H; Nagata T; Ninomiya N
    J Dermatol; 2018 Jun; 45(6):701-709. PubMed ID: 29665062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis.
    Saeki H; Ohya Y; Baba N; Imamura T; Yokota D; Tsubouchi H
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2443-2455. PubMed ID: 39075274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
    Schlessinger J; Shepard JS; Gower R; Su JC; Lynde C; Cha A; Ports WC; Purohit V; Takiya L; Werth JL; Zang C; Vlahos B;
    Am J Clin Dermatol; 2020 Apr; 21(2):275-284. PubMed ID: 32212104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study.
    Kubota Y; Yoneda K; Nakai K; Katsuura J; Moriue T; Matsuoka Y; Miyamoto I; Ohya Y
    J Am Acad Dermatol; 2009 Feb; 60(2):212-7. PubMed ID: 19027990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delgocitinib in atopic dermatitis.
    Ho J; Molin S
    Drugs Today (Barc); 2021 Dec; 57(12):719-731. PubMed ID: 34909801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Delgocitinib Ointment 0.5% on the Normal Mouse Skin and Epidermal Tight Junction Proteins in Comparison With Topical Corticosteroids.
    Anagawa-Nakamura A; Ryoke K; Yasui Y; Shoda T; Sugai S
    Toxicol Pathol; 2020 Dec; 48(8):1008-1016. PubMed ID: 33334258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
    Eichenfield LF; Call RS; Forsha DW; Fowler J; Hebert AA; Spellman M; Stein Gold LF; Van Syoc M; Zane LT; Tschen E
    J Am Acad Dermatol; 2017 Oct; 77(4):641-649.e5. PubMed ID: 28823881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.